The short version of storage stability fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-07-31 and is reviewed periodically as new material appears.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form; visual inspection |
| Solubility | Soluble in water and aqueous buffers | Depends on pH, purity, and counterion |
| Typical storage | -20 °C or below, desiccated | Protect from light; avoid repeated freeze-thaw after reconstitution |
| Common analytical method | Reversed-phase HPLC and mass spectrometry | Purity by HPLC; identity and mass by LC-MS or MALDI-TOF |
| Common synonyms | hGH fragment 176–191; AOD-9604 | Names vary in research and product labeling |
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
=== Culinary use === The leaves and shoots can be eaten raw, having a bitter flavor. They can also be cooked like spinach or are sometimes added to salads. An extract is sometimes added as a flavoring in vodkas.
=== Buccal administration === Progesterone has been studied for use by buccal administration. The medication has been marketed in the form of buccal tablets under the brand names Progesterone Lingusorbs, Lutocylol, Membrettes, and Syngestrets, although these products are no longer available. The clinical dosage of buccal progesterone has been described as 10 to 50 mg/day relative to 5 to 60 mg/day in the case of intramuscular injection.
== Protein structure and Terminology == Proteins are chains of amino acids joined together by peptide bonds. Many conformations of this chain are possible due to the rotation of the main chain about the two torsion angles φ and ψ at the Cα atom. This conformational flexibility is responsible for differences in the three-dimensional structure of proteins.
{\displaystyle {\begin{aligned}\Delta p={\frac {1}{2}}\rho {\overline {v}}_{\text{max}}^{2}&={\frac {1}{2}}\rho \left({\frac {Q_{\text{max}}}{\pi R^{2}}}\right)^{2}\\\Rightarrow \quad Q_{\max }{}&=\pi R^{2}{\sqrt {\frac {2\Delta p}{\rho }}},\end{aligned}}}
Sources: en.wikipedia.org
== Further reading == Collip, James (May 1941). "Frederick Grant Banting, Discoverer of Insulin". The Scientific Monthly. 52 (5): 472–474. Bibcode:1941SciMo..52..472C. JSTOR 17312. Banting, F.G. & Best, C.H. (1922), "The Internal Secretions of the Pancreas", The Journal of Laboratory and Clinical Medicine, Vol.7, No.5, (February 1922), pp. 251–266. Banting, F.G., Best, C.H., Collip, J.B., Campbell, W.R. & Fletcher, A.A. (1922), "Pancreatic Extracts in the Treatment of Diabetes Mellitus", The Canadian Medical Association Journal, Vol.12, No.3, (March 1922), pp.141–146. US patent no.1,469,994 (held by "Frederick G. Banting and Charles Herbert Best, of Toronto, Ontario, and James Bertram Collip of Edmonton, Alberta, Canada"), (filed: 12 January 1923), (patented: 9 October 1923), for "Extract Obtainable from the Mammalian Pancreas or from the Related Glands in Fishes, Useful in the Treatment of Diabetes Mellitus, and a Method of Preparing it". Best, C. H. (November 1, 1942). "Frederick Grant Banting 1891–1941". Obituary Notices of Fellows of the Royal Society. 4 (11): 20–26. doi:10.1098/rsbm.1942.0003. S2CID 162239410. Bliss, Michael (1992) [1984]. Banting: A Biography. Toronto, Ontario: University of Toronto Press. ISBN 978-0-8020-7387-7. Banting, F. G.; Best, C. H. (2009). "The Journal of Laboratory and Clinical Medicine: Vol. VII St. Louis, February, 1922 No. 5". Nutrition Reviews. 45 (4): 55–57. doi:10.1111/j.1753-4887.1987.tb07442.x. PMID 3550540. Bliss, Michael (1990) [1982]. The Discovery of Insulin (3rd ed.). University of Toronto Press. ISBN 978-0-8020-8344-9.
After Geelong under Thompson were eliminated from the preliminary finals to Collingwood, at the conclusion of the 2010 season, on 4 October 2010, Thompson announced his retirement and resignation as Geelong Football Club senior coach effective immediately, his reason being that he was "tired of coaching" after a decade at the helm. Thompson was replaced by Chris Scott as Geelong Football club senior coach.
=== Miscellaneous === The US Food and Drug Administration (FDA) advises that donation of blood or plasma be deferred for at least one month after taking the last dose of finasteride. The UK also has a one-month deferral period.
=== 3D structures === Zhou H, McCarthy B, O'Connor M, Reed J, Stoops K (Dec 2001). "The remarkable structural and functional organization of the eukaryotic pyruvate dehydrogenase complexes". Proceedings of the National Academy of Sciences of the United States of America. 98 (26): 14802–14807. Bibcode:2001PNAS...9814802Z. doi:10.1073/pnas.011597698. ISSN 0027-8424. PMC 64939. PMID 11752427., bovine kidney pyruvate dehydrogenase complex Yu X, Hiromasa Y, Tsen H, Stoops K, Roche E, Zhou H (Jan 2008). "Structures of the Human Pyruvate Dehydrogenase Complex Cores: A Highly Conserved Catalytic Center with Flexible N-Terminal Domains". Structure. 16 (1): 104–114. doi:10.1016/j.str.2007.10.024. ISSN 0969-2126. PMC 4807695. PMID 18184588., human full-length and truncated E2 (tE2) cores of PDC, expressed in E. coli
2C (2C-x) is a general name for the family of psychedelic phenethylamines containing methoxy groups on the 2 and 5 positions of a benzene ring. Most of these compounds also carry lipophilic substituents at the 4 position, usually resulting in more potent and more metabolically stable and longer acting compounds. Most of the early 2C drugs were developed by Alexander Shulgin in the 1970s and 1980s and were reviewed in his 1991 book PiHKAL (Phenethylamines I Have Known And Loved). 2C-B is the most popular of the 2C drugs. The prefix "2C" comes from the fact that they are phenethylamines rather than amphetamines and have two carbon atoms in their side chain, whereas the suffix (e.g., the "–B" or "bromo" in the case of 2C–B) refers to the substituent at the 4-position.
Sources: en.wikipedia.org
==== Mortality ==== The World Health Organization reports that babies who receive no breast milk are almost six times more likely to die by the age of one month than those who are partially or fully breastfed. Access to healthcare is the single critical determinant of survival or death for the infant.
=== Isometric activity === In 1993, isometric exercise training was applied for four weeks resulting in isometric peak power at 60% of maximal voluntary contraction. The increase in isometric power was later shown to have no significant effect on serum creatine kinase (CK) after two weeks of strength training.
==== 600–699 ==== Appropriation (Northern Ireland) Order 1993 (S.I. 1993/600) Insurance (Fees) Regulations 1993 (S.I. 1993/601) Insolvency (Amendment) Rules 1993 (S.I. 1993/602) Civil Jurisdiction and Judgments Act 1982 (Amendment) Order 1993 (S.I. 1993/603) Civil Jurisdiction and Judgments (Authentic Instruments and Court Settlements) Order 1993 (S.I. 1993/604) Maximum Number of Judges Order 1993 (S.I. 1993/605) Maximum Number of Judges (Northern Ireland) Order 1993 (S.I. 1993/606) Air Navigation (Fourth Amendment) Order 1993 (S.I. 1993/607) National Health Service (Travelling Expenses and Remission of Charges) Amendment Regulations 1993 (S.I. 1993/608) Further Education (Attribution of Surpluses and Deficits) Regulations 1993 (S.I. 1993/609) Veterinary Surgeons and Veterinary Practitioners (Registration) (Amendment) Regulations Order of Council 1993 (S.I. 1993/610) Education (Welsh Agricultural College Higher Education Corporation) (Designated Staff) Order 1993 (S.I. 1993/611) Education (Further Education Corporations) (Designated Staff) (Wales) Order 1993 (S.I. 1993/612) Local Government Finance (Payments) (Welsh Authorities) Regulations 1993 (S.I. 1993/613) National Board for Nursing, Midwifery and Health Visiting for Wales (Constitution and Administration) Order 1993 (S.I. 1993/614) Valuation and Community Charge Tribunals (Amendment) (No. 2) Regulations 1993 (S.I. 1993/615) Local Government Finance (Repeals, Savings and Consequential Amendments) Order 1993 (S.I.
=== Photodetector === A graphene/n-type silicon heterojunction has been demonstrated to exhibit strong rectifying behavior and high photoresponsivity. By introducing a thin interfacial oxide layer, the dark current of graphene/n-Si heterojunction has been reduced by two orders of magnitude at zero bias. At room temperature, the graphene/n-Si photodetector with interfacial oxide exhibits a specific detectivity up to 5.77 × 1013 cm Hz1/2 W2 at the peak wavelength of 890 nm in vacuum. In addition, the improved graphene/n-Si heterojunction photodetectors possess high responsivity of 0.73 A W−1 and high photo-to-dark current ratio of ≈107. These results demonstrate that graphene/Si heterojunction with interfacial oxide is promising for the development of high detectivity photodetectors. Recently, a graphene/si Schottky photodetector with record-fast response speed (< 25 ns) from wavelength 350 nm to 1100 nm are presented. The photodetectors exhibit excellent long-term stability even stored in air for more than 2 years. These results not only advance the development of high-performance photodetectors based on the graphene/Si Schottky junction, but also have important implications for mass-production of graphene-based photodetector array devices for cost-effective environmental monitoring, medical images, free-space communications, photoelectric smart-tracking, and integration with CMOS circuits for emerging interest-of-things applications, etc.
Sources: en.wikipedia.org
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.
Mass spectrometry, such as LC-MS or MALDI-TOF, confirms the molecular mass and can reveal sequence-related impurities. Reversed-phase HPLC is used for purity, and peptide mapping or amino acid analysis can support sequence identity. No single method establishes every quality attribute.
No. AOD9604 is a short synthetic fragment of the hGH sequence, not the full 191-amino-acid hormone. It lacks the regions that mediate hGH receptor activation and growth-promoting effects. Products labeled as AOD9604 should not be assumed to have the same properties as hGH.
Reversed-phase HPLC is used to assess purity, and mass spectrometry confirms molecular mass. Amino acid analysis can verify composition. These methods are standard for peptide characterization.